文献速递淋巴瘤造血干细胞移植与细胞治疗

高危单难治与双难治慢性淋巴细胞白血病的alloHCT可行性与影响

High-risk single-refractory and double-refractory chronic lymphocytic leukemia: feasibility and impact of alloHCT.
PubMed 文献 · Blood Adv · 2026-01-01

本研究纳入47例高危慢性淋巴细胞白血病患者,比较对cBTKi或BCL2i单难治(SRHR)与双难治(DR)患者的预后,并探讨异基因造血干细胞移植(alloHCT)的结局。SRHR队列中位无事件生存22个月,SRHR和DR队列中位总生存分别为51和21个月。22例接受alloHCT,2年非复发死亡率19%、复发率19%、无进展生存率62%、总生存率67%,但探索性比较未显示alloHCT显著总生存获益。

要点

  • 高危单难治CLL预后差但优于双难治,中位OS分别为51和21个月。
  • alloHCT可行,2年NRM 19%、复发率19%、PFS 62%、OS 67%。
  • 探索性比较未显示alloHCT显著OS获益,获益与时机待定。

核心结论

  • 高危单难治CLL预后差但优于双难治。
  • alloHCT可行且可能克服临床与生物学难治,但确切获益和时机待确定。

研究设计与样本

  • 研究纳入47例患者,40例进入研究时为SRHR状态,7例为DR状态。
  • 17例从SRHR演变为DR,故DR总人群共24例。

主要发现

  • SRHR队列中78%对cBTKi难治、22%对BCL2i难治,90%存在TP53异常。
  • SRHR队列中位无事件生存(定义为下一线进展或死亡)为22个月。
  • SRHR和DR队列中位总生存分别为51和21个月。
  • 22例接受alloHCT,2年非复发死亡率19%、复发率19%、无进展生存率62%、总生存率67%。
  • 探索性比较移植与未移植患者未显示alloHCT显著总生存获益。

关键数值与推荐

  • SRHR队列中78%对cBTKi难治、22%对BCL2i难治。
  • SRHR患者中90%存在TP53异常。
  • SRHR队列中位无事件生存22个月,中位总生存51个月;DR队列中位总生存21个月。
  • alloHCT后2年非复发死亡率19%、复发率19%、无进展生存率62%、总生存率67%。

临床怎么用

  • 对cBTKi或BCL2i单难治的高危CLL患者,可考虑alloHCT但需权衡获益与时机。
  • 双难治患者预后极差,alloHCT可作为可选策略但获益未证实。

局限性

  • 样本量小(47例),探索性比较未显示显著OS获益。
  • alloHCT的确切获益和时机仍需确定。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

This study aimed to compare the prognosis of patients with chronic lymphocytic leukemia (CLL) harboring TP53 abnormalities or a complex karyotype who are refractory to a covalent Bruton kinase inhibitors (cBTKi) or B-cell lymphoma 2 inhibitors (BCL2i; single-refractory high-risk [SRHR] genetics) with that of patients refractory to both cBTKi and BCL2i (double-refractory [DR]), and to investigate the outcome of allogeneic hematopoietic cell transplantation (alloHCT) in these settings. Overall, 47 patients were included. Of these, 40 patients entered the study in SRHR status, and 7 patients in DR status. Because 17 patients evolved from having SRHR to DR status over time, the total DR population comprised 24 patients. In the SRHR cohort, 78% had cBTKi-refractory and 22% had BCL2i-refractory disease, and TP53 abnormalities were in present in 90% of the patients with SRHR. Median event-free survival (defined as progression on next line, or death) of the SRHR cohort was 22 months; and median overall survival (OS) of the SRHR and DR cohorts was 51 and 21 months, respectively. A total of 22 patients underwent alloHCT; their nonrelapse mortality, relapse incidence, progression-free survival, and OS at 2 years was 19%, 19%, 62%, and 67%, respectively. Although long-term progression-free survivors were observed after transplantation, exploratory comparisons of patients who received a transplant and those who did not did not show a significant OS benefit in favor of alloHCT. In conclusion, the outlook of patients with high-risk single-refractory CLL is dismal but better than in patients with DR disease. In both settings, alloHCT is feasible and may overcome clinical and biological disease refractoriness; however, its exact benefit and timing remain to be determined.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Kauer J, Krämer I, Derigs P, et al. High-risk single-refractory and double-refractory chronic lymphocytic leukemia: feasibility and impact of alloHCT. Blood Adv. 2026. PMID: 42284699. doi:10.1182/bloodadvances.2026020219

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。